Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: An effect controlled by the thioredoxin system

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Sun, Yu ^a   Rowehl, Leahana M ^a   Huang, Liqun ^a   Mackenzie, Gerardo G ^a   Vrankova, Kvetoslava ^a   Komninou, Despina ^b   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Medicon Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; MDC 917; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOIBUPROFEN; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; THIOREDOXIN; THIOREDOXIN 1; UNCLASSIFIED DRUG; 2 (4 ISOBUTYLPHENYL)PROPIONIC ACID 4 (DIETHOXYPHOSPHORYLOXY)BUTYL ESTER; 2-(4-ISOBUTYLPHENYL)PROPIONIC ACID 4-(DIETHOXYPHOSPHORYLOXY)BUTYL ESTER; APOPTOSIS SIGNAL REGULATING KINASE 1; CYCLOOXYGENASE 2; DRUG DERIVATIVE; GLUTATHIONE; IBUPROFEN; MAP3K5 PROTEIN, HUMAN; ORGANOPHOSPHATE; PTGS2 PROTEIN, MOUSE; REACTIVE NITROGEN SPECIES; THIOREDOXIN REDUCTASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; XENOGRAFT; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; OXIDATION REDUCTION REACTION; PROTEIN BINDING; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2; FEMALE; GLUTATHIONE; HUMANS; IBUPROFEN; LIPOSOMES; MAP KINASE KINASE KINASE 5; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPHOSPHATES; OXIDATION-REDUCTION; PROTEIN BINDING; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862800814     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3105     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, Komninou D, Rigas B. The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol 2011, 162:1521-1533. 10.1111/j.1476-5381.2010.01162.x, 3057290, 21175575.
3. Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, Komninou D, Rigas B. Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 2011, 337:876-886. 10.1124/jpet.111.180224, 21422165.
4. Arner ES. Focus on mammalian thioredoxin reductases - important selenoproteins with versatile functions. Biochim Biophys Acta 2009, 1790:495-526. 10.1016/j.bbagen.2009.01.014, 19364476.
5. Mukherjee A, Martin SG. The thioredoxin system: a key target in tumour and endothelial cells. Br J Radiol 2008, 81(Spec No 1):S57-S68.
6. Holmgren A, Sengupta R. The use of thiols by ribonucleotide reductase. Free Radic Biol Med 2010, 49:1617-1628. 10.1016/j.freeradbiomed.2010.09.005, 20851762.
7. Koneru S, Varma Penumathsa S, Thirunavukkarasu M, Vidavalur R, Zhan L, Singal PK, Engelman RM, Das DK, Maulik N. Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. J Cell Mol Med 2008, 12:2651-2664. 10.1111/j.1582-4934.2008.00319.x, 18373738.
8. Berndt C, Lillig CH, Holmgren A. Thioredoxins and glutaredoxins as facilitators of protein folding. Biochim Biophys Acta 2008, 1783:641-650. 10.1016/j.bbamcr.2008.02.003, 18331844.
9. Yoshioka J, Schreiter ER, Lee RT. Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal 2006, 8:2143-2151. 10.1089/ars.2006.8.2143, 17034356.
10. Kaimul AM, Nakamura H, Masutani H, Yodoi J. Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med 2007, 43:861-868. 10.1016/j.freeradbiomed.2007.05.032, 17697931.
11. Benz CC, Yau C. Ageing, oxidative stress and cancer: paradigms in parallax. Nat Rev 2008, 8:875-879.
12. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulphide bond involving cysteine 62. Nucl Acids Res 1992, 20:3821-3830. 10.1093/nar/20.15.3821, 334054, 1508666.
13. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997, 94:3633-3638. 10.1073/pnas.94.8.3633, 20492, 9108029.
14. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. Embo J 1998, 17:2596-2606. 10.1093/emboj/17.9.2596, 1170601, 9564042.
15. Nishinaka Y, Masutani H, Oka S, Matsuo Y, Yamaguchi Y, Nishio K, Ishii Y, Yodoi J. Importin α1 (Rch1) mediates nuclear translocation of thioredoxin-binding protein-2/vitamin D(3)-up-regulated protein 1. J Biol Chem 2004, 279:37559-37565. 10.1074/jbc.M405473200, 15234975.
16. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword?. Antioxid Redox Signal 2007, 9:2277-2293. 10.1089/ars.2007.1782, 17979528.
17. Zhang K. Integration of ER stress, oxidative stress and the inflammatory response in health and disease. Int J Clin Exp Med 2010, 3:33-40. 2848304, 20369038.
18. Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 2006, 16:420-426. 10.1016/j.semcancer.2006.10.009, 17092741.
19. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K, Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 2005, 11:8425-8430. 10.1158/1078-0432.CCR-05-0449, 16322305.
20. Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 2007, 7:392-397. 10.1016/j.coph.2007.04.003, 17611157.
21. Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, Gius D. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr Pharm Des 2007, 13:3368-3377. 10.2174/138161207782360537, 18045191.
22. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004, 83:249-289. 10.1023/B:BREA.0000014042.54925.cc, 14758095.
23. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 1994, 54:2615-2621.
24. Cailleau R, Young R, Olive M, Reeves WJ. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974, 53:661-674.
25. Sun Y, Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 2008, 68:8269-8277. 10.1158/0008-5472.CAN-08-2010, 18922898.
26. Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, Jones DP. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J Biol Chem 2003, 278:33408-33415. 10.1074/jbc.M211107200, 12816947.
27. Williams JL, Ji P, Ouyang N, Liu X, Rigas B. NO-donating aspirin inhibits the activation of NF-κB in human cancer cell lines and Min mice. Carcinogenesis 2008, 29:390-397. 2679698, 18174252.
28. Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, Johnson F, Komninou D, Kopelovich L, Rigas B. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology 2010, 139:1320-1332. 10.1053/j.gastro.2010.06.044, 2949489, 20600034.
29. Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, Kashfi K, Rigas B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res 2006, 66:4503-4511. 10.1158/0008-5472.CAN-05-3118, 16618778.
30. Gomez E, Gutierrez-Adan A, Diez C, Bermejo-Alvarez P, Munoz M, Rodriguez A, Otero J, Alvarez-Viejo M, Martin D, Carrocera S, Caamaño JN. Biological differences between in vitro produced bovine embryos and parthenotes. Reproduction 2009, 137:285-295.
31. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991, 88:11460-11464. 10.1073/pnas.88.24.11460, 53155, 1763060.
32. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006, 17:587-595. 10.1097/00001813-200606000-00014, 16702817.
33. O'Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 2003, 4:318-328. 10.3816/CBC.2003.n.037, 14715106.
34. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 2010, 63:161-169.
35. Maruyama K, Yuda T, Okamoto A, Kojima S, Suginaka A, Iwatsuru M. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta 1992, 1128:44-49.
36. Sun Y, Huang L, Mackenzie GG, Rigas B. Oxidative stress mediates through apoptosis the anticancer effect of phospho-NSAIDs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther 2011, 338:775-783. 10.1124/jpet.111.183533, 21646387.
37. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983, 130:1910-1917.
38. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992, 5:227-231. 10.1021/tx00026a012, 1322737.
39. Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med 2009, 30:1-12. 10.1016/j.mam.2008.08.006, 2696075, 18796312.
40. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009, 17:55-67. 10.1007/s10787-009-8049-8, 19340409.
41. Sun Y, Chen J, Rigas B. Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis 2009, 30:93-100. 2639032, 18952595.
42. Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 2005, 70:969-986. 10.1016/j.bcp.2005.05.004, 15949789.
43. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010, 48:749-762. 10.1016/j.freeradbiomed.2009.12.022, 2823977, 20045723.
44. Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T, Tohyama M. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFκB activation in primary hippocampal neurons. J Biol Chem 1999, 274:8531-8538. 10.1074/jbc.274.13.8531, 10085086.
45. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002, 21:5673-5683. 10.1038/sj.onc.1205664, 12173037.
46. Rigas B, Sun Y. Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br J Cancer 2008, 98:1157-1160. 10.1038/sj.bjc.6604225, 2359637, 18253125.
47. Sun Y, Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 2008, 68:8269-8277. 10.1158/0008-5472.CAN-08-2010, 18922898.
48. Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, Komninou D, Rigas B. The novel phospho-NSAIDs OXT-328, MDC-22 and MDC-917 inhibit adjuvant-induced arthritis in the rat. Br J Pharmacol 2011, 162:1521-1533. 10.1111/j.1476-5381.2010.01162.x, 3057290, 21175575.
49. Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 2007, 47:143-183. 10.1146/annurev.pharmtox.47.120505.105122, 17029566.
50. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 2010, 396:120-124. 10.1016/j.bbrc.2010.03.083, 20494123.